* Shockwave Medical Inc SWAV.OQ SWAV.O is expected
to show a
rise in quarterly revenue when it reports results on February
16.
* The Santa Clara California-based company is expected to
report
a 69.4% increase in revenue to $142.602 million from $84.18
million a year ago, according to the mean estimate from 7
analysts, based on Refinitiv data. The company's guidance on
January 17 2023, for the period ended December 31, was for
revenue between $143.00 million and $144.00 million.
* Refinitiv's mean analyst estimate for Shockwave Medical
Inc is
for earnings of $1.01 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Shockwave
Medical
Inc is $256, above its last closing price of $186.32.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 0.67 0.67 0.92 Beat 37.6
Jun. 30 2022 0.44 0.44 0.68 Beat 54.5
Mar. 31 2022 0.18 0.18 0.39 Beat 111.6
Dec. 31 2021 0.11 0.09 0.34 Beat 300
Sep. -0.05 -0.06 0.05 Beat 187.5
30 2021
Jun. 30 2021 -0.37 -0.40 -0.01 Beat 97.5
Mar. 31 2021 -0.46 -0.45 -0.68 Missed -52.2
Dec. 31 2020 -0.42 -0.42 -0.46 Missed -8.7
This summary was machine generated February 14 at 23:34 GMT.
All figures in US dollars unless otherwise stated